According to Zhitong Finance App, Hanson Pharmaceuticals (03692) announced that on March 14, 2024, Hanson (Shanghai) Health Technology Co., Ltd., a wholly-owned subsidiary of the company, signed a license agreement with the licensee Pumis Biotechnology (Zhuhai) Co., Ltd. (Pumis).
According to the license agreement, the licensee obtained an exclusive license from Pumis to develop, produce and commercialize HS-20117 (introduction project name PM1080) for bispecific antibody conjugate products (ADC products) worldwide, and has the right to further sub-license. The licensee will pay a total of no more than RMB 5 billion for initial payments and potential payments for ADC-based product development, registration, and commercialization milestones based on sales, and tiered royalties based on global net sales.
Under the 2022 license agreement, the licensee received an exclusive license from Pumis to develop and commercialize the HS-20117/ PM1080 in China. This new license will further enrich the Group's R&D pipeline.
HS-20117/pm1080 is an EGFR/cMet bispecific antibody with a 1+1 heterologous dimer structure. It inhibits tumor growth and survival by specifically targeting the tumor antigens EGFR and cMet, and is currently in phase I clinical research.